Short Stature in Moyamoya Disease: A Systematic Review of Potential Mechanisms and Clinical Outcomes.

IF 1.6 Q3 PERIPHERAL VASCULAR DISEASE
Stroke Research and Treatment Pub Date : 2025-09-08 eCollection Date: 2025-01-01 DOI:10.1155/srat/5550395
Abdallah M Mujbel, Lea Nohra, Haidar Karrar T Sabih, Rania H Al-Taie
{"title":"Short Stature in Moyamoya Disease: A Systematic Review of Potential Mechanisms and Clinical Outcomes.","authors":"Abdallah M Mujbel, Lea Nohra, Haidar Karrar T Sabih, Rania H Al-Taie","doi":"10.1155/srat/5550395","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Moyamoya disease (MMD) is a complex cerebrovascular disorder. While its neurological manifestations are well documented, the association between MMD and short stature remains underrecognized. This review explores potential mechanisms linking MMD with growth impairment, with a focus on endocrine and syndromic contributors. <b>Methods:</b> A systematic review was conducted in accordance with PRISMA guidelines using PubMed and Scopus databases. Studies reporting cases of MMD with short stature or growth impairment were included. Data were extracted on patient demographics, endocrine findings, genetic mutations, neuroimaging, management, and outcomes. A narrative synthesis approach was used due to heterogeneity in study designs. <b>Results:</b> Across 25 studies, 30 individuals with MMD and clinically significant short stature were identified, predominantly pediatric (2.5-52 years). Presentations frequently included seizures (<i>n</i> = 21), TIAs (<i>n</i> = 8), hemiparesis (<i>n</i> = 7), cognitive impairment (<i>n</i> = 8), and headaches (<i>n</i> = 3); in many, growth failure predated neurological events. Height deficits ranged from -2.13 to -23.7 SDS. Endocrine involvement was common: growth hormone deficiency (<i>n</i> ≈ 6), delayed bone age (<i>n</i> = 3), and other pituitary-thyroid-gonadal disturbances; a rare pituitary stalk duplication was reported. Management varied. Indirect revascularization in selected cases reduced recurrent ischemia; growth hormone therapy improved height velocity. Antiplatelets were commonly used; anticoagulation occasionally led to complications. Outcomes were heterogeneous; four deaths occurred, typically in patients with severe multisystem disease. <b>Conclusion:</b> Growth retardation in MMD is generally a manifestation of hypothalamic-pituitary dysfunction, chronic cerebral hypoxia, or genetic syndromes. The observations in the present study suggest that MMD may be part of a more generalized multisystemic disorder in some patients and needs multisystemic assessment and management.</p>","PeriodicalId":22054,"journal":{"name":"Stroke Research and Treatment","volume":"2025 ","pages":"5550395"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436000/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Stroke Research and Treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/srat/5550395","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Moyamoya disease (MMD) is a complex cerebrovascular disorder. While its neurological manifestations are well documented, the association between MMD and short stature remains underrecognized. This review explores potential mechanisms linking MMD with growth impairment, with a focus on endocrine and syndromic contributors. Methods: A systematic review was conducted in accordance with PRISMA guidelines using PubMed and Scopus databases. Studies reporting cases of MMD with short stature or growth impairment were included. Data were extracted on patient demographics, endocrine findings, genetic mutations, neuroimaging, management, and outcomes. A narrative synthesis approach was used due to heterogeneity in study designs. Results: Across 25 studies, 30 individuals with MMD and clinically significant short stature were identified, predominantly pediatric (2.5-52 years). Presentations frequently included seizures (n = 21), TIAs (n = 8), hemiparesis (n = 7), cognitive impairment (n = 8), and headaches (n = 3); in many, growth failure predated neurological events. Height deficits ranged from -2.13 to -23.7 SDS. Endocrine involvement was common: growth hormone deficiency (n ≈ 6), delayed bone age (n = 3), and other pituitary-thyroid-gonadal disturbances; a rare pituitary stalk duplication was reported. Management varied. Indirect revascularization in selected cases reduced recurrent ischemia; growth hormone therapy improved height velocity. Antiplatelets were commonly used; anticoagulation occasionally led to complications. Outcomes were heterogeneous; four deaths occurred, typically in patients with severe multisystem disease. Conclusion: Growth retardation in MMD is generally a manifestation of hypothalamic-pituitary dysfunction, chronic cerebral hypoxia, or genetic syndromes. The observations in the present study suggest that MMD may be part of a more generalized multisystemic disorder in some patients and needs multisystemic assessment and management.

Abstract Image

Abstract Image

烟雾病中身材矮小:潜在机制和临床结果的系统综述。
背景:烟雾病是一种复杂的脑血管疾病。虽然其神经系统表现已被充分证明,但烟雾病与身材矮小之间的关系仍未得到充分认识。这篇综述探讨了烟雾病与生长障碍的潜在机制,重点是内分泌和综合征因素。方法:根据PRISMA指南使用PubMed和Scopus数据库进行系统评价。研究报告的病例烟雾病与身材矮小或生长障碍包括在内。提取患者人口统计学、内分泌发现、基因突变、神经影像学、管理和结果的数据。由于研究设计的异质性,采用了叙事综合方法。结果:在25项研究中,确定了30例烟雾病和临床显着身材矮小的个体,主要是儿科(2.5-52岁)。常见症状包括癫痫发作(n = 21)、tia (n = 8)、偏瘫(n = 7)、认知障碍(n = 8)和头痛(n = 3);在许多情况下,生长衰竭早于神经系统疾病。身高缺陷范围从-2.13到-23.7 SDS。内分泌受累是常见的:生长激素缺乏(n≈6),骨龄延迟(n = 3),以及其他垂体-甲状腺-性腺紊乱;报道了一种罕见的垂体柄重复。管理不同。间接血运重建术可减少复发性缺血;生长激素治疗提高了身高速度。常用抗血小板药物;抗凝偶尔会导致并发症。结果是异质的;发生了4例死亡,通常是患有严重多系统疾病的患者。结论:烟雾病的生长迟缓通常是下丘脑-垂体功能障碍、慢性脑缺氧或遗传综合征的表现。本研究的观察结果表明,烟雾病可能是某些患者更广泛的多系统疾病的一部分,需要多系统评估和管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Stroke Research and Treatment
Stroke Research and Treatment PERIPHERAL VASCULAR DISEASE-
CiteScore
3.20
自引率
0.00%
发文量
14
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信